Technology
4s3 Bioscience is an emerging science-driven company focused on the development of bio-therapeutics for degenerative muscle diseases. The company’s therapies are based on a proprietary intracellular delivery technology platform that takes advantage of tissue targeting via a novel antibody (3E10) and intracellular delivery dependent on membrane expression of a nucleoside transporter (ENT2). Because the ENT2 transporter is naturally enriched in skeletal muscle fibers (and elevated in certain cancers), 4s3 is able to generate proprietary product candidates utilizing substrates (proteins, enzymes, etc.) not previously deliverable to target tissues (skeletal muscle and cancers); thereby, providing a novel way to treat a number of diseases with limited or no current therapeutic options.